Hetero Of India Gets Major Government Order For Tamiflu Generic
This article was originally published in PharmAsia News
Indian drug maker Hetero Drugs has been asked by India's government to supply 10 million doses of a generic version of Roche's Tamiflu (oseltamivir) to treat the H1N1 virus. Hetero received the contract because it has the license from Roche to produce a generic in India. The firm outbid Cipla, Natco, Ranbaxy and Roche India to supply the drug to the government. Hetero said it would supply two million doses within days and another five million by the end of May, with the entire order to be completed by mid-June. (Click here for more
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.